Regadenoson
Astellas CMR Tagging
Approved small_molecule completed
Quick answer
Regadenoson for Coronary Artery Disease is a Approved program (small_molecule) at Aspire Biopharma Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aspire Biopharma Holdings
- Indication
- Coronary Artery Disease
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed